Charles River Laboratories International (CRL) Short Interest Ratio & Short Volume → Better than Bitcoin? The Biotech Stock with 46,751% Potential (From Behind the Markets) (Ad) Free CRL Stock Alerts $229.03 +1.22 (+0.54%) (As of 04/26/2024 ET) Add Compare Share Share Short InterestStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Charles River Laboratories International Short Interest DataCurrent Short Volume1,910,000 sharesPrevious Short Volume1,580,000 sharesChange Vs. Previous Month+20.89%Dollar Volume Sold Short$450.63 millionShort Interest Ratio / Days to Cover3.6Last Record DateApril 15, 2024Outstanding Shares51,510,000 sharesPercentage of Shares Shorted3.71%Today's Trading Volume322,036 sharesAverage Trading Volume486,257 sharesToday's Volume Vs. Average66% Short Selling Charles River Laboratories International ? Sign up to receive the latest short interest report for Charles River Laboratories International and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort InterestDays to CoverShort Percent of FloatCRL Short Interest Over TimeCRL Days to Cover Over TimeCRL Percentage of Float Shorted Over Time Ad Behind the MarketsBetter than Bitcoin? The Biotech Stock with 46,751% Potential4x Better than Bitcoin Bitcoin would have to go from $68,000 to $314,000 to match the 463% gains we saw with Immunogen in December.Get the name of the stock here >>> Charles River Laboratories International Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 4/15/20241,910,000 shares $450.63 million +20.9%N/A3.6 $235.93 3/31/20241,580,000 shares $428.10 million -0.6%N/A2.8 $270.95 3/15/20241,590,000 shares $411.76 million -9.1%N/A2.9 $258.97 2/29/20241,750,000 shares $444.83 million -8.9%N/A3.1 $254.19 2/15/20241,920,000 shares $471.30 million +14.3%3.8%3.6 $245.47 1/31/20241,680,000 shares $363.20 million +27.3%N/A3.2 $216.19 Get the Latest News and Ratings for CRL and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Charles River Laboratories International and its competitors with MarketBeat's FREE daily newsletter. 1/15/20241,320,000 shares $279.17 million -12.0%N/A2.4 $211.49 12/31/20231,500,000 shares $354.60 million -8.5%N/A2.9 $236.40 12/15/20231,640,000 shares $378.53 million +11.6%N/A3.2 $230.81 11/30/20231,470,000 shares $289.71 million -9.8%N/A2.8 $197.08 11/15/20231,630,000 shares $305.74 million -3.0%N/A3.1 $187.57 10/31/20231,680,000 shares $282.84 million -4.0%N/A3.3 $168.36 10/15/20231,750,000 shares $334.29 million +4.8%N/A3.8 $191.02 9/30/20231,670,000 shares $327.29 million -1.8%N/A3.6 $195.98 9/15/20231,700,000 shares $353.40 million +10.4%N/A3.5 $207.88 8/31/20231,540,000 shares $318.50 million +11.6%N/A3.4 $206.82 8/15/20231,380,000 shares $289.90 million +9.5%N/A2.9 $210.07 7/31/20231,260,000 shares $264.02 million -3.8%2.5%2.5 $209.54 7/15/20231,310,000 shares $271.90 million -9.0%2.6%2.5 $207.56 6/30/20231,440,000 shares $302.76 million -5.9%2.9%2.8 $210.25 6/15/20231,530,000 shares $319.75 million +11.7%3.1%2.9 $208.99 5/31/20231,370,000 shares $264.96 million +2.2%2.7%2.5 $193.40 5/15/20231,340,000 shares $257.76 million -13.0%2.7%2.2 $192.36 4/30/20231,540,000 shares $292.78 million +11.6%N/A2.7 $190.12 4/15/20231,380,000 shares $281.09 million +2.2%2.8%2.5 $203.69 3/31/20231,350,000 shares $272.46 million +3.9%2.7%2.4 $201.82 3/15/20231,300,000 shares $253.37 million -0.8%2.6%2.3 $194.90 2/28/20231,310,000 shares $287.34 million +11.0%2.6%2.3 $219.34 2/15/20231,180,000 shares $296.81 million +3.5%2.4%2 $251.53 1/31/20231,140,000 shares $277.31 million +11.8%2.3%1.9 $243.25 1/15/20231,020,000 shares $237.27 million +1.0%N/A1.6 $232.62 12/30/20221,010,000 shares $220.08 million -2.9%N/A1.7 $217.90 12/15/20221,040,000 shares $227.24 million +17.6%N/A1.6 $218.50 11/30/2022884,200 shares $202.10 million -8.4%N/A1.4 $228.57 11/15/2022965,300 shares $241.39 million -19.6%N/A1.6 $250.07 10/31/20221,200,000 shares $254.70 million -8.4%N/A2 $212.25 10/15/20221,310,000 shares $258.36 million +14.9%N/A2.2 $197.22 9/30/20221,140,000 shares $224.35 million -12.3%N/A2 $196.80 9/15/20221,300,000 shares $264.69 million +28.7%N/A2.4 $203.61 8/31/20221,010,000 shares $207.30 million -1.9%N/A1.9 $205.25Better than Bitcoin? The Biotech Stock with 46,751% Potential (Ad)4x Better than Bitcoin Bitcoin would have to go from $68,000 to $314,000 to match the 463% gains we saw with Immunogen in December.Get the name of the stock here >>> CRL Short Interest - Frequently Asked Questions What is Charles River Laboratories International's current short interest? Short interest is the volume of Charles River Laboratories International shares that have been sold short but have not yet been covered or closed out. As of April 15th, investors have sold 1,910,000 shares of CRL short. Learn More on Charles River Laboratories International's current short interest. What is a good short interest ratio for Charles River Laboratories International? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. CRL shares currently have a short interest ratio of 4.0. Learn More on Charles River Laboratories International's short interest ratio. Which institutional investors are shorting Charles River Laboratories International? As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of Charles River Laboratories International: Capstone Investment Advisors LLC, Concourse Financial Group Securities Inc., and Simplex Trading LLC. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission. Is Charles River Laboratories International's short interest increasing or decreasing? Charles River Laboratories International saw a increase in short interest during the month of April. As of April 15th, there was short interest totaling 1,910,000 shares, an increase of 20.9% from the previous total of 1,580,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. How does Charles River Laboratories International's short interest compare to its competitors? Here is how the short interest of companies in the sector of "medical" compare to Charles River Laboratories International: Medpace Holdings, Inc. (3.97%), Incyte Co. (3.68%), ICON Public Limited (1.93%), IQVIA Holdings Inc. (1.58%), Shockwave Medical, Inc. (3.93%), Karuna Therapeutics, Inc. (5.16%), Fresenius Medical Care AG (0.19%), Revvity, Inc. (2.93%), Dr. Reddy's Laboratories Limited (0.45%), DaVita Inc. (4.22%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: T-Mobile US, Inc. ($3.70 billion), Occidental Petroleum Co. ($3.52 billion), Charter Communications, Inc. ($3.14 billion), General Motors ($2.68 billion), Coinbase Global, Inc. ($2.57 billion), Moderna, Inc. ($2.18 billion), Tractor Supply ($2.10 billion), Royal Caribbean Cruises Ltd. ($1.91 billion), TC Energy Co. ($1.90 billion), and Williams-Sonoma, Inc. ($1.78 billion). View all of the most shorted stocks. What does it mean to sell short Charles River Laboratories International stock? Short selling CRL is an investing strategy that aims to generate trading profit from Charles River Laboratories International as its price is falling. CRL shares are trading up $1.22 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Charles River Laboratories International? A short squeeze for Charles River Laboratories International occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of CRL, which in turn drives the price of the stock up even further. How often is Charles River Laboratories International's short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including CRL, twice per month. The most recent reporting period available is April, 15 2024. More Short Interest Resources from MarketBeat Related Companies: MEDP Short Squeeze INCY Short Squeeze ICLR Short Squeeze IQV Short Squeeze SWAV Short Squeeze KRTX Short Squeeze FMS Short Squeeze RVTY Short Squeeze RDY Short Squeeze DVA Short Squeeze Short Interest Tools: Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NYSE:CRL) was last updated on 4/27/2024 by MarketBeat.com Staff From Our PartnersThese AI trades triggered this morning (545% return)Prosper Trading AcademyConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsHe Is Giving Away BitcoinCrypto Swap ProfitsThe A.I. story nobody is telling you (Read ASAP)TradeSmithThe World's First "$20 Trillion Drug?"Behind the MarketsFed launches fourth dollar overhaulStansberry ResearchBiden out June 13; Kamala won’t replace him?Paradigm PressMan Who Predicted 2008: “This Will be Worse.”Altimetry